All News

A cancer survivor recalls some experiences he had along his journey and reminds others to be the CEO of their care team, as it’s their life on the line.

Although “social distancing” has become a common term used to describe the safe distance people keep from others to avoid contracting COVID-19, stage 1 ovarian cancer survivor and teacher Brenda Kowalski reminds patients who may be starting out on their cancer journey that it’s important to not “socially distance” yourself from friends when you need support.

Recent study results show an association between living in an area of socioeconomic deprivation and poor outcomes for patients with cancer who were treated in clinical trials.

A prostate cancer survivor recalls a time when the cancer center’s staff helped him realize that its OK to have fun while receiving cancer treatment.

Abecma is the first cell-based gene therapy approved for the treatment of patients with relapsed and refractory multiple myeloma who did not respond to at least four treatments, or whose disease returned after those four lines of therapy.

New clinical trials open doors for positive changes in treatment of colorectal cancer.

A woman who is living with metastatic breast cancer pens a tribute to a late friend and fellow patient, Penny, who continues to send her signs that help her keep going.

It is difficult for anyone to receive a cancer diagnosis, but when someone who is younger than average finds out they have gastrointestinal cancer, they may face other challenges.

Doctors and survivors urge women to consider the future both before and after receiving a cancer diagnosis.

Although Keytruda did not improve overall survival when compared with chemotherapy, patients with a higher PD-L1 expression may derive a greater benefit with Keytruda, as shown with a longer median overall survival.

A cancer survivor yearns for the “touch starvation” brought on by the COVID-19 pandemic to be over. She writes about how just one hug can make a huge difference for people.

From a Baltimore restaurant owner traveling six hours to cook for a terminally ill customer to the death of a pioneer in breast cancer treatment, here’s what’s happening in the cancer landscape this week.

Rozlytrek continues to demonstrate clinical benefit for patients with ROS1 fusion-positive non-small cell lung cancer, which includes patients with central nervous system metastases.

Although COVID-19 has shaken our lives in so many ways, it’s important to keep our health one of our top priorities while also staying safe. We must find widely acceptable ways to screen for cancer in this new era so that we don’t turn the clock back on the gains we have made in the past few decades.

CURE® spoke with Monica Fawzy Bryant, chief operating officer of Triage Cancer, about health insurance options and what patients with cancer need to know.

Many cancer survivors may feel the urge to use their disease as a convenient excuse for avoiding unpleasant situations, writes a survivor. However, she urges others to avoid giving into that power.

Here is a list of some recent trials that launched within the cancer space in March.

There is a lot of hype on T-cell engagers and CAR T-cell therapy, but there are other new and exciting immunotherapies in myeloma not talked about that may be approved in the near future, according to an expert.

The biggest reason the FDA’s recent approval of Fotivda is important for adults with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies, according to an expert from the Vanderbilt-Ingram Cancer Center, is that it offers them a very tolerable treatment option that may preserve quality of life.

The old saying is that spring is the season of hope, and this cancer caregiver writes how it feels like this spring has a bit more bounce in its step.

A new technology that can detect small amounts of circulating tumor DNA in the blood of patients who previously received a diagnosis of certain types of cancer may dramatically accelerate the ability to cure more patients, says an expert from the University of Texas MD Anderson Cancer Center.

In a recent interview with CURE®, an expert from Fox Chase Cancer Center discussed gastrointestinal stromal tumors (GIST) and addressed a multitude of topics including common symptoms associated with the disease, and potential future therapies that may be beneficial for patients.

Results of a preliminary clinical trial show that MK-1775 — an investigational therapy — as a single agent, or in combination with Ayvakit, may be effective in the treatment of gastrointestinal stromal tumors. However, one of the study’s authors notes that further research is needed to determine a benefit in patients.

Data from a recent study demonstrates that patients with breast cancer — especially those who are younger, privately insured, of non-White race and lower-income — are more likely to file for bankruptcy than those without cancer.

A patient with metastatic cancer writes what it has been like to face the dilemma of receiving an effective cancer therapy that may put her heart at risk.

The identification of rare genomic alterations in patients with colorectal cancer gives oncologists the opportunity to treat patients who otherwise might not have many options.

The phase 3 ARIEL4 trial evaluated Rubraca (rucaparib) versus chemotherapy in patients with ovarian cancer and a BRCA mutation who did not respond to two or more lines of chemotherapy.

Keytruda in combination with chemotherapy has just received FDA approval for the treatment of patients with metastatic or locally advanced esophageal and gastroesophageal cancers.

For patients with B-cell lymphoma, the addition of Revlimid to standard R-CHOP did not improve progression-free survival nor event-free survival.

On social media, CURE® recently asked its readers to offer advice to others looking to help friends and family who have been diagnosed with cancer. Here is some of their advice.